Skip to main content

NINLARO® (ixazomib) capsules 4mg I 3mg I 2.3mg

VELCADE® (bortezomib) FOR INJECTION

This site is intended for US healthcare professionals only.

Important Safety Information Prescribing Information
Menu

This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

NINLARO® (ixazomib) capsules 4mg I 3mg I 2.3mg

VELCADE® (bortezomib) FOR INJECTION

This site is intended for US healthcare professionals only.

Important Safety Information Prescribing Information

SAFETY

NINLARO® (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Warnings and Precautions

  • Warnings and Precautions associated with NINLARO include thrombocytopenia, gastrointestinal toxicities, peripheral neuropathy, peripheral edema, cutaneous reactions, thrombotic microangiopathy, hepatotoxicity, and embryo-fetal toxicity
  • For additional details about these Warnings and Precautions, see the Important Safety Information below.

Selected safety profile

Nonhematologic ARs occurring in 5% of patients with a 5% difference between ORAL NINLARO+Rd AND Rd IN TOURMALINE-MM11*
Nonhematologic adverse events: NINLARO® (ixazomib) vs. placebo

Additional safety information

  • Serious ARs reported in ≥2% of patients included thrombocytopenia (2%) and diarrhea (2%)1
  • Incidence of thrombocytopenia in patients in the NINLARO and Rd regimens, respectively: any grade, 78% vs 54%; grades 3-4, 26% vs 11%1
  • Incidence of neutropenia in the NINLARO and Rd regimens, respectively: any grade, 67% vs 66%; grades 3-4, 26% vs 30%1
  • *The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The Rd regimen included placebo+lenalidomide+dexamethasone.
  • Represents a pooling of preferred terms.
  • AR=adverse reaction.

Overall safety profile among high-risk and standard-risk cytogenetics patients10

  • The overall safety profiles in the high-risk and standard-risk cytogenetics patients in each group are consistent with data reported for the overall population
  • As seen in the overall population, in both high-risk and standard-risk cytogenetics patients, common adverse events were primarily of grade 1 or 2 severity and included diarrhea, constipation, neutropenia, and anemia
  • Rates of adverse events of clinical importance were also consistent with previous reports
  • Defined as patients with del(17p), t(4;14), and/or t(14;16).

The NINLARO® (ixazomib) regimen demonstrated a safety profile amenable to treatment to disease progression1,3

DISCONTINUATION RATES DUE TO ARs WERE SIMILAR TO THOSE IN THE Rd REGIMEN IN TOURMALINE-MM19
13% vs 11% with NINLARO® and Rd regimens, respectively
  • *The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The Rd regimen included placebo+lenalidomide+dexamethasone.
Dose Tolerability
80%

of patients continued at the starting dose of NINLARO without dose reduction.9

  • For each adverse reaction, 1 or more of the 3 drugs were discontinued in ≤1% of patients in the NINLARO regimen
  • 8% of high-risk cytogenetic patients discontinued the NINLARO regimen because of adverse events vs 13% with the Rd regimen10
  • Defined as patients with del(17p), t(4;14), and/or t(14;16).

The most common adverse reactions (≥20%) in the NINLARO regimen and greater than the placebo regimen, respectively, were diarrhea (42%, 36%), constipation (34%, 25%), thrombocytopenia (78%, 54%; pooled from adverse events and laboratory data), peripheral neuropathy (28%, 21%), nausea (26%, 21%), peripheral edema (25%, 18%), vomiting (22%, 11%), and back pain (21%, 16%). Serious adverse reactions reported in ≥2% of patients included thrombocytopenia (2%) and diarrhea (2%).